| 日付 | 受信時刻 | ニュースソース | 見出し | コード | 企業名 |
| 2024/04/25 | 05 : 00 | GlobeNewswire Inc. | Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2024/02/26 | 14 : 15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2024/02/23 | 06 : 38 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2024/02/23 | 06 : 36 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2024/02/23 | 06 : 33 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2024/02/23 | 06 : 32 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2024/02/23 | 06 : 28 | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration statement | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2024/02/21 | 05 : 22 | Edgar (US Regulatory) | Form SC 13E3/A - Going private transaction by certain issuers: [Amend] | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2024/02/20 | 21 : 13 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2024/02/20 | 21 : 00 | GlobeNewswire Inc. | Acquisition of Freeline by Syncona Becomes Effective | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2024/02/13 | 06 : 01 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2024/02/13 | 02 : 00 | GlobeNewswire Inc. | Freeline Shareholders Approve Acquisition by Syncona | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2024/01/19 | 06 : 15 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2024/01/18 | 06 : 17 | Edgar (US Regulatory) | Form SC 13E3/A - Going private transaction by certain issuers: [Amend] | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2023/12/09 | 07 : 21 | Edgar (US Regulatory) | Form SC 13E3 - Going private transaction by certain issuers | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2023/12/01 | 22 : 56 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2023/11/22 | 23 : 20 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2023/11/22 | 21 : 30 | GlobeNewswire Inc. | Syncona to Acquire Freeline Therapeutics | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2023/10/25 | 19 : 01 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2023/10/25 | 15 : 01 | GlobeNewswire Inc. | Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2023/10/18 | 20 : 00 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2023/10/16 | 20 : 00 | GlobeNewswire Inc. | Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual Congress | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2023/10/07 | 05 : 52 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2023/10/04 | 20 : 00 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2023/10/04 | 20 : 00 | GlobeNewswire Inc. | Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2023/08/15 | 20 : 00 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2023/08/15 | 20 : 00 | GlobeNewswire Inc. | Freeline Reports Second Quarter 2023 Financial Results and Business Highlights | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2023/08/08 | 20 : 30 | GlobeNewswire Inc. | Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2023/07/31 | 20 : 30 | GlobeNewswire Inc. | Freeline to Participate in Upcoming Investor Conferences | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |
| 2023/07/25 | 20 : 30 | GlobeNewswire Inc. | Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher Disease | NASDAQ:FRLN | Freeline Therapeutics Holdings PLC |